Corteva, Inc.

The filings show a larger top line and higher net income in 2025 than in 2024, but the first-quarter 2026 filing shows the balance sheet moving the other way. Revenue rose about 2.9% to $17.4 billion, and net income rose about 20% to $1.09 billion. Total assets were $42.84 billion at December 31, 2025, up from $40.83 billion a year earlier. Annual totals do not show the intra-year pattern of seasonal working capital, which the MD&A says is funded through commercial paper, the Revolving Credit Facilities, the 364-Day Revolving Credit Facility and factoring. The company reports $6.7 billion of committed and uncommitted unused credit lines at March 31, 2026, and says it was in compliance with a total indebtedness to total capitalization covenant of 0.60. Readers may want to look at Note 8 on receivables and Note 12 on guarantees, since the MD&A says the company guarantees part of some third-party customer financing and gives recourse on some factored receivables. The risk-factor section also covers regulatory exposure: challenges to pesticide registrations including Enlist One, PFAS remediation at Chemours' Fayetteville Works facility under an MOU with Chemours and DuPont, and pending FTC and state attorney general lawsuits. No forensic scores are on file for this analysis, so this synthesis does not characterize any Beneish, Piotroski, Altman or readability result. The reported figures therefore rest on the company's own statements, and readers may want to compare the Proposed Separation terms and the timing of the pension contribution against the next annual and quarterly filings.

Catalyst.Corteva's reported 2025 revenue was $17.4 billion, up from $16.91 billion in 2024, and net income was $1.09 billion, up from $907 million. The filings describe a business built on seed hybrids, biotechnology traits and crop protection products, with growth depending on pipeline products reaching market. The company is also pursuing a Proposed Separation into two independent companies, which the MD&A says are expected to have strong balance sheets and investment grade credit ratings. The first-quarter 2026 MD&A centers on seasonal working capital, a $250 million share repurchase under the 2024 Share Buyback Plan, and a quarterly dividend of $0.18 per share.

Hidden risk.The easiest tension to miss is in cash. Cash, cash equivalents and marketable securities fell from $4,530 million at December 31, 2025 to $1,966 million at March 31, 2026, while total debt rose from $2,580 million to $3,356 million. Operating cash flow from continuing operations was an outflow of $2,885 million in the first quarter of 2026, which the MD&A attributes to the Bayer resolution payment and higher compensation payments. The board has also approved a contribution of about $1.5 billion to the principal U.S. pension plan by July 31, 2026. The risk factors add pending FTC and state attorney general lawsuits and a December 6, 2025 executive order that could restrict acquisitions.